Seeking Alpha

Immunogen (IMGN)

()

News & PR
Market Currents

Buzz
Twitter: IMGN

Business Intelligence
Transcripts
Events
Key Developments

Analysis - Latest Articles by most recent | most commented

Immunogen's Busy Month, Part II

Dec 2 • Ohad Hammer • Comment!
December's Game Plan for Biotech

Dec 1 • Justin M. Hall • 4 Comments
Immunogen's Busy Month, Part I

Dec 1 • Ohad Hammer • Comment!
13 Biotechs to Watch for at Hematology Conference

Nov 30 • Michael Becker • Comment!
37 Breakout Stocks on Big Volume, November 16, 2009

Nov 17 • Marco Hickey • 2 Comments
Incyte: Life After Debt (Part I)

Oct 14 • Ohad Hammer • Comment!
Three Life Science Companies Line Up for IPOs

Sep 21 • The Burrill Report • Comment!
Spectrum Pharmaceuticals: Despite Share Offering, Still Cheap vs. Other Cancer Drugmakers

Sep 20 • Justin M. Hall • 3 Comments
Spectrum Pharma: Post-Zevalin Approval Sales Should Ramp Up

Sep 11 • Justin M. Hall • 23 Comments
Micromet: The Clock Is Ticking

Aug 24 • Ohad Hammer • Comment!
Curagen: Positive Results at ASCO 2009

Jul 7 • Ohad Hammer • 2 Comments
Pharma M&A: Big Bonds and Small Deals

Jun 26 • The Burrill Report • Comment!
A Healthy Dose of Funding for Pharma, Biotech

Jun 21 • The Burrill Report • Comment!
Healthcare Stocks Continue to Rise

Jun 19 • M. E. Garza • Comment!
FDA, Clinical Trial Calendars: Cancer Drug Updates from ASCO

Jun 1 • Mike Havrilla • 2 Comments
Top Biotech Picks for ASCO 2009 (Part II)

May 27 • Ohad Hammer • 2 Comments
Clinical Trial Updates: Cancer Drugs in Focus as ASCO Approaches

May 18 • Mike Havrilla • 1 Comment
FDA, Clinical Trial Calendar Updates: AstraZeneca Announces Phase III Results

May 12 • Mike Havrilla • Comment!
Bright Prospects for Micromet (Part 2)

Apr 24 • Ohad Hammer • 3 Comments
Immunogen: Moving on Up

Mar 27 • Beta Delta • Comment!
Good News for Roche and Excellent News For Immunogen

Mar 20 • Ohad Hammer • Comment!
20 'Bathwater Babies' and 3 'Dogs with Fleas' for the Week

Mar 2 • J Clinton Hill • 5 Comments
Genentech's Trastuzumab-Dm1 Shows Great Promise in Treating Breast Cancer

Jan 6 • Beta Delta • 3 Comments
Immunogen and Exelixis Defy the Recession

Dec 22, 2008 • Ohad Hammer • Comment!
Time to Buy ImmunoGen

Dec 4, 2008 • Beta Delta • Comment!
Why It's Time to Buy More Immunogen

Oct 17, 2008 • Ohad Hammer • Comment!
Genentech's Decision Should Boost Immunogen Stock

Oct 15, 2008 • Ohad Hammer • Comment!
'When There's Blood in the Streets', Buy Biotech Stocks

Oct 10, 2008 • Ohad Hammer • 13 Comments
Genentech’s New ADC Platform Has Much Potential, but Is Yet to Be Tested on Humans

Aug 6, 2008 • Ohad Hammer • 2 Comments
Immunogen's Wild Swings Due to Lack of Information at ASCO

Jul 14, 2008 • Ohad Hammer • 3 Comments
Immunogen and Seattle Genetics: Verging on an Inflection Point

May 27, 2008 • Ohad Hammer • 4 Comments
ASCO: Whose Presentations Look the Most Promising?

May 27, 2008 • Dan Rosenblum • 2 Comments
Why is Wall Street Ignoring ImmunoGen?

May 16, 2008 • Beta Delta • 5 Comments
The Future of ImmunoGen - Care of Genentech

Mar 17, 2008 • Beta Delta • 1 Comment
Micromet: Biting Cancer

Feb 6, 2008 • Ohad Hammer • 1 Comment
ImmunoGen at ASH 2007 (Part II)

Dec 30, 2007 • Ohad Hammer • Comment!
ImmunoGen at ASH 2007 (Part I)

Dec 30, 2007 • Ohad Hammer • 1 Comment
PowerHouse Week for Economic Calendar

Oct 29, 2007 • Michael Shaffer • 1 Comment
Immunogen's Bright Future (Part II)

Oct 18, 2007 • Ohad Hammer • 4 Comments
Immunogen’s Bright Future

Oct 9, 2007 • Ohad Hammer • 4 Comments
The "Naked" Truth About Antibodies For Cancer Therapy

Jul 5, 2007 • Ohad Hammer • 3 Comments

Immunogen (IMGN)

Analysis - Latest Articles by most recent | most commented

The Seeking Alpha 100

Fastest Climbers

Top Commenters

Top Instabloggers

Top StockTalkers